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Chagas disease caused by the protozoan parasite Trypanosoma cruzi is endemic in
21 Latin American countries and the southern United States and now is spreading
into several other countries due to migration. Despite the efforts to control the vector
throughout the Americas, currently, there are almost seven million infected people
worldwide, causing ∼10,000 deaths per year, and 70 million people at risk to acquire
the infection. Chagas disease treatment is restricted only to two parasiticidal drugs,
benznidazole and nifurtimox, which are effective during the acute and early infections but
have not been found to be as effective in chronic infection. No prophylactic or therapeutic
vaccine for human use has been communicated at this moment. Here, we evaluate in a
mouse model a therapeutic DNA vaccine combining Cruzipain (Cz), a T. cruzi cysteine
protease that proved to be protective in several settings, and Chagasin (Chg), which is the
natural Cz inhibitor. The DNAs of both antigens, as well as a plasmid encoding GM-CSF
as adjuvant, were orally administrated and delivered by an attenuated Salmonella strain to
treat mice during the acute phase of T. cruzi infection. The bicomponent vaccine based
on Salmonella carrying Cz and Chg (SChg+SCz) was able to improve the protection
obtained by each antigen as monocomponent therapeutic vaccine and significantly
increased the titers of antigen- and parasite-specific antibodies. More importantly, the
bicomponent vaccine triggered a robust cellular response with interferon gamma (IFN-γ)
secretion that rapidly reduced the parasitemia during the acute phase and decreased the
tissue damage in the chronic stage of the infection, suggesting it could be an effective
tool to ameliorate the pathology associated to Chagas disease.
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INTRODUCTION
Chagas disease, caused by the protozoan parasite Trypanosoma
cruzi, is endemic in 21 Latin American countries and the
southern United States and now is spreading, due to migration,
into several other countries (1, 2). Despite the efforts of theWorld
Health Organization and Pan American Health Organization (3)
to control the vector throughout the Americas, currently, there
are almost seven million infected people worldwide, causing
∼10,000 deaths per year by complication linked to Chagas
disease, and 70 million people at risk to acquire the infection (4).
Although vector control and screening tests before blood
transfusions and organ transplantation have successfully
achieved substantial reduction in the number of new acute cases
in endemic areas (5), complete control of T. cruzi is currently
unaffordable. Despite vector control programs effectively
reducing the level of infestation, when they are not sustained
over time, reinfection of treated households reaches levels like
the initial one (6). This was mainly seen in rural areas, when
constructions are poor or in peridomestic areas with domestic
animals (7). Several concerns remain a challenge, namely,
disease globalization due to migration (1, 8); the existence of
alternative routes of transmission, such as mother-to-child or
oral transmission through contaminated food or beverages (9);
and the high variability in drug sensitivity across multiple strains
of T. cruzi (10).
Despite the fact that 100 years has passed since the discovery
of Chagas disease, the treatment is restricted only to two
parasiticidal drugs, benznidazole, and nifurtimox, developed in
the 1970s and 1960s, respectively. The long-course treatments
with these therapeutics ensure efficacy during the early stage
of the infection (11); however, they have poor success when
administered during the chronic phase of the infection.
Moreover, they have severe adverse effects, causing up to 40% of
dropout of the treatment and resistance issues being described
(12, 13). In this context, safer and more effective drugs or
therapeutic vaccines are urgently needed (14, 15).
T. cruzi contains a major cysteine proteinase, Cruzipain (Cz),
which is expressed by all developmental forms and strains of
the parasite; it is secreted and can also be found in the parasite
membrane. Parasite virulence and morphogenesis depend on the
endogenous activity of the lysosomal Cz (16). In addition, it
has been proved that Cz is essential for amastigote replication
and plays a crucial role in host–parasite interactions (17).
Cz stimulates potent humoral and cellular immune responses
during infection (18). Additionally, Cz has been reported as an
efficient prophylactic vaccine as both protein and DNA vaccine,
in different administration routes and coupled with several
adjuvants (19–24). In addition, we had encouraging results
using a therapeutic Cz DNA-based vaccine that has been able
to decrease parasitemia, inflammatory cell infiltrate, and tissue
damage in murine models of T. cruzi infection (25).
Cysteine protease inhibitors have been explored as novel anti-
T. cruzi therapeutic strategies (26–28). Chagasin (Chg), a T.
cruzi natural protein, is a tight-binding inhibitor of papain-
like cysteine proteases. Chg regulates the endogenous activity of
Cz, finely modulating proteolytic functions essential for parasite
differentiation and invasion to mammalian cells, compromising
the virulence and morphogenesis of the parasite. Detailed
structural studies showed that Chg is associated with the native
cysteine protease in the Golgi compartment (29). However, the
proportion of unbound Cz is higher, so only a small amount is
found to form the Cz–Chg complex. Actually, this association
may be related to the prevention of Cz autocatalysis. It also
has been reported that trypomastigotes overexpressing Chg are
less infective than wild-type parasites (29). Moreover, Chg is
expressed in all developmental stages of T. cruzi and can be
localized in the flagellar pocket and cytoplasmic vesicles of
trypomastigotes and to the cell surface of amastigotes, being
an antigen recognized by sera from chronic T. cruzi-infected
patients (30). The endogenous regulation of Cz by Chg influences
important aspects of T. cruzi biology, such as morphogenesis,
sensitivity to synthetic inhibitors, and infectivity of the parasite
(30). These points signal Chg as a relevant antigen to include in a
prophylactic or therapeutic vaccine against T. cruzi infection, not
yet exhaustively investigated.
Based on these backgrounds, we evaluate here a combined
strategy with the DNA of both Cz and Chg as therapeutic vaccine,
looking for a robust and balanced immune response effective in
decreasing blood and tissue parasites and also the characteristic
tissue damage of T. cruzi infection.
MATERIALS AND METHODS
Parasites
Blood T. cruzi trypomastigotes of the RA strain (discrete typing
unit (DTU) VI) were isolated from acutely infected mice at
the parasitemia peak. Parasite passages were performed weekly
in 21-day-old CF1 mice. After 15 days post infection (dpi),
parasites were obtained by centrifugation (10,000 × g, 30min)
from heparinized blood. Epimastigotes of the same parasite strain
were grown in liver infusion tryptose (LIT) medium at 27◦C to
the exponential phase of growth and centrifuged at 3,000× g for
15min as previously described (31).
To obtain a soluble antigenic fraction, epimastigotes of T.
cruzi (RA strain) were centrifuged for 15min at 5,000 × g.
The pellet was resuspended in 0.25M sucrose and 5mM KCl
containing protease inhibitors (2µM PMSF, 5µM leupeptin,
5µM pepstatin, and 5µM E-64; Sigma, St. Louis, MO), and
parasites were lysed by three cycles of freezing and thawing. The
homogenate was centrifuged at 105,000 × g for 1 h at 4◦C, and
the supernatant containing T. cruzi-soluble antigens was called
fraction 105 (F105). The presence of different protein bands in
the complex antigen was verified by 10% SDS-PAGE, and F105
was aliquoted and conserved at−20◦C.
Antigens
Purified T. cruzi epimastigote DNAwas used as a template for the
amplification of Cz and Chg. Cz gene was cloned as described by
Cazorla et al. (19). Chg amplification was performed using the
following primers: Fw 5′-gtcatgcatatgggtgcttgtgggtcgaag-3′ and
Rev 5′-gtcatggaattctcagtggtggtggtggtggtgcgcgctctccggcacgttg-3′.
The PCR was performed at an annealing temperature of 56◦C
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using a Platinum Taq DNA Polymerase (Invitrogen, Carlsbad,
CA). The 333-bp fragment was purified from a 1% agarose gel.
The amplified fragment was digested with the NdeI and
HindIII restriction enzymes, inserted into a pET23a plasmid and
transformed in Escherichia coli XL2-Blue. The presence of the
insert was confirmed by sequence analysis, and the recombinant
plasmid was used to transform BL21 cells. Protein expression was
induced with 1mM IPTG ON at 20◦C.
rChg was purified under native conditions with growing
concentrations of imidazole using a Ni+2-nitrilotriacetic acid–
Sepharose matrix. After dialysis in PBS–glycerol 10%, the purity
and identity of Chg were analyzed. Endotoxins were removed
by a polymyxin B–agarose column (Sigma, St. Louis, MO).
Endotoxin levels in the final protein preparations were <100
units/mg, as determined using a Limulus amebocyte lysate
analysis kit (Whittaker Bioproducts, Walkersville, MD).
The catalytic activity of cysteine proteases was measured in a
continuous test using the fluorogenic substrate, Z-Phe-Arg-AMC
(Bachem). The fluorescence reading of 7-aminomethyl coumarin
(AMC) released was measured with a Victor3 fluorometer
(PerkinElmer) every 10 seg (λexcitation = 355 nm/λemission
= 460 nm). Increasing concentrations of Chg (0.01–10 µg)
were evaluated against epimastigote lysates (5µM) and the N-
terminal domain of Cz (NtCz, 6 µg) previously cloned and
expressed (20). The synthetic inhibitor E-64 (10µM) was used
as positive control.
Chg gene for DNA vaccination was cloned in the
eukaryotic plasmid pcDNA3.1(+), using the primers
fw: 5′-tgatgttgaattcgtaatgtcccacaaggtgacg-3′ and rev: 5′-
gtcatgggatcctcagtttgccttgagatatacagtg-3′ that contain the
cutoff sites for restriction enzymes, the Kozak sequence, the
ATG code for proper transcription, and the TCA termination
code. The digested fragment, with the enzymes EcoRI and
BamHI, was ligated to the plasmid pcDNA3.1(+) (Invitrogen,
Life Technologies). Positive transformed E. coli DH-5α clones
were selected on plates with LB–ampicillin medium. In purified
DNA (QIAGEN kit), the presence of the insert of interest was
confirmed by digestion with the corresponding restriction
enzymes and subsequent sequencing.
Additionally, the Chg-pcDNA3.1 plasmid was used for
transforming electrocompetent bacteria Salmonella enterica
serovar Typhimurium aroA SL7207, which were used as a DNA
delivery system as described previously (32).
Animals
C3H/HeN mice were maintained in the animal facilities of
the Instituto de Microbiología y Parasitología Médica (IMPaM,
UBA-CONICET) under standard conditions following the
Review Board of Ethics of the School of Medicine, UBA,
Argentina (Resol. CD #3721/2014) and the guidelines established
by the National Research Council (33). Animal experiments
were approved by the Review Board of Ethics of the School of
Pharmacy and Biochemistry (UBA, Argentina) and conducted
in accordance with the National Institutes of Health guide for
the care and use of laboratory animals (NIH Publications No.
8023, 2011). Animal sample size was estimated by a power-
basedmethod (34) and following the guidelines established by the
National Research Council PREPARE guidelines in the design of
experiments (35).
Challenge and Therapy
Immunotherapeutic studies were performed on 6–8-week-old
female C3H/HeN mice. Groups of five mice infected with 50
(sublethal dose) or 1,000 (lethal dose) blood trypomastigotes of
the RA strain were treated by the oral administration of 109
CFU/dose/mouse of aroA-attenuated Salmonella transformed
with the different plasmids encoding the antigens or the adjuvant
(32). The groups are as follows: (I) SControl, attenuated
Salmonella as carriers of granulocyte-macrophage colony-
stimulating factor (GM-CSF) DNA (SGM-CSF); (II) SChg. two
attenuated Salmonella, one transformed with Chg DNA and
the other with GM-CSF DNA; (III) SCz, one Salmonella with
the Cz gene and SGM-CSF; and (IV) SChg+SCz, Salmonella
transporting the Chg, Cz, and GM-CSF plasmids.
Acute treatments consisted of three doses of the DNA
transported by Salmonella on 0, 10, and 20 dpi. Chronic
treatment was administered on 100, 110, and 120 dpi. Blood
and tissue samples from the mice were taken 100 days after the
last immunization.
Treatment Efficacy
Parasitemia and Weight Loss
After challenge with trypomastigotes of T. cruzi, blood parasites
were counted every 2 days, until the end of the acute phase of
infection, as previously described (25). Survival and weight of the
animals were recorded daily until they were sacrificed.
Specific Immune Response Analyses
Determination of specific antibodies elicited by the vaccines was
performed by an indirect ELISA against a complex mixture of
soluble T. cruzi antigens called F105 (10µg/ml) or against rCz
or rChg (2µg/ml). Titers were calculated as the inverse of the
highest dilution in which the optical density is higher than 0.1.
A delayed-hypersensitivity test (DTH) was performed on day
100 post treatment by measuring the thickness of the footpads
prior and 48 h post inoculation of 5 µg of rCz or rChg.
Spleen cell proliferation assays were performed at the end of
the experiments in the presence of rCz or rChg (10µg/ml), F105
(100µg/ml), Con A (5µg/ml), or medium alone (control) by
triplicate. Eighteen hours before the harvest, 1 µCi per well of
thymidine (H)3 (Amersham) was added. Proliferative response
was expressed as the difference between cpm values obtained
from stimulated and nonstimulated cultures.
Splenocyte stimulation by the different antigens was also
measured as the intracellular production of interferon gamma
(IFN-γ) in a flow cytometry assay. In the last 12 h of incubation,
brefeldin A was added to the cultures. Cells were fixed at room
temperature (RT) with PFA 2%, permeabilized in 0.5% saponin,
and stained using anti-IFN-γ (e-Bioscience conjugated antibody)
in accordance with the manufacturer’s instructions. Stained cells
were passed through the BD FACS II flow cytometer, and data
were analyzed with Flow JoX software 10.0.7.
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Muscle Injury
A hundred days after the last immunization (120 dpi), muscle
damage was assessed by measuring the serum activity of creatine
kinase (CK and CK-MB), following the instructions of the
manufacturer (Wiener Lab).
Histological analyses were also performed at the same time,
for which the mice were euthanized, and the corresponding
necropsy was performed. The section of muscle (quadriceps) and
the complete cardiovascular block were removed. Both ventricles
and atria were dissected, and the left ventricle (LV) was cut from
the apex to base, fixed in phosphate-buffered 10% formaldehyde
at pH 7.2, and embedded in paraffin wax.
Tissues were sectioned into multiple, consecutive 5-µm
cross sections with a Reichert–Jung micrometer (Nußloch,
Germany) for light microscopic observation as previously
described (21). For each heart and skeletal muscle, 20 random
microscopic fields were counted at 400×magnification. Sections
were evaluated under blind conditions. The lesion severity
was assessed based on semiquantitative criteria according
to the inflammation index: (1) isolated foci; (2) multiple
nonconfluent foci; (3) multiple confluent foci; and (4) multiple
diffuse foci, as previously described (36). Regarding the
heart, histological examinations of the LV, right ventricle,
and septum were conducted. The presence of fibrosis in the
heart sections was evaluated with Masson’s trichrome stain
without considering the perivascular collagen for each of
the groups.
In addition, on the day of euthanasia, 100mg of
skeletal and cardiac muscles was extracted to quantify the
parasite burden in each tissue, as described (37). The DNA
extraction was made by a phenol–chloroform–isoamyl alcohol
mixture (25:24:1 v/v, Quick-DNA, Kalium Technologies).
The template for DNA amplification was adjusted to 25
ng/µl. Specific T. cruzi primers were used for the DNA
amplification (Pr: 5′-AAGCGGATAGTTCAGGG-3′, Pf: 5
′
-
GGCGGATCGTTTTCGAG-3′). As for the normalized gene,
samples were also amplified with mouse TNF-α primers
(Pf: 5′-CCCTCTCATCAGTTCTATGGCCCA-3′, Pr: 5′-
CAGCAAGCATCTATGCACTTAGACCCC-3′). PCR was
performed using HOT FIRE Pol Eva Green qPCRMix Plus (Solis
Biodyne). The standard was performed by mixing 500mg of
noninfected mouse muscle with 1 × 108 T. cruzi epimastigotes.
After the extraction, the DNA was adjusted to 25 ng/µl. For
the curve, 10-fold serial dilution of the standard was made
using noninfected mouse muscle DNA (25 ng/µl) as diluent.
Parasite burden was expressed as parasite equivalent per 50 ng of
total DNA.
Statistical Analysis
Statistical analyses were carried out with GraphPad Prism
6.0 software (San Diego, CA, USA) using one-way analysis
of variance (ANOVA) for proliferation, antibody, enzyme
activity assays, and parasitemia. Normality was verified
using the Shapiro–Wilks test. The specific posttest was
indicated in each assay. The log-rank test was used for
survival curves, using the Prism 6.0 program (GraphPad,
San Diego, CA). The statistical analyses were referred to the
control group of each experiment. Values of p < 0.05 were
considered significant.
RESULTS
Cloning and Characterization of Chg
In order to analyze the humoral and cellular-specific response
after the therapeutic treatment, Chg and Cz were produced
as recombinant proteins. Cz was previously cloned by Cazorla
et al. (19). Chg gene was amplified from epimastigote gDNA
and cloned in pET23a+ plasmid. The obtained pET23a+ Chg
vector was digested with NdeI and HindIII restriction enzymes,
releasing a 400-bp fragment visualized on a 1% agarose gel
(Figure 1A). After sequence confirmation, this vector was used to
transform E. coli BL21. Chg was obtained as a soluble protein and
purified under native conditions; a 12-kDa band in SDS-PAGE
was observed (Figure 1B).
To analyze whether rChg maintains the capacity to inhibit
cysteine protease activity of the natural Chg, we analyzed the
inhibition of enzymatic activity on the fluorogenic substrate Z-
Phe-Arg-AMC. High contents of cysteine proteases, including
Cz, are present in the T. cruzi replicative epimastigote stage, and
we observed that rChg was able to inhibit the activity from lysed
epimastigotes with a similar slope to the commercial synthetic
inhibitor (E-64) used as positive control (Figure 1C). To analyze
rChg-specific inhibitory capacity on Cz, the catalytic domain of
Cz (rNtCz) was assayed in the presence or absence of rChg, and
a well-defined concentration-dependent inhibition was observed
(Figure 1D).
SChg+SCz as a Therapeutic Vaccine
Against a Lethal T. cruzi Infection
To improve the therapeutic effect afforded by Cz DNA (25),
we evaluated the coadministration with Chg DNA. Mice lethally
infected with T. cruzi (1,000 RA trypomastigotes/mouse) were
treated with three doses of Salmonella delivering the DNA
encoding for GM-CSF (SGM-CSF) as adjuvant and Chg (SChg),
Cz (SCz), or a combination of both (SChg+SCz). The control
group was treated with Salmonella carrying only the DNA of
GM-CSF (SControl) (Figure 2A).
During the acute phase of the infection, all treated mice
showed an important decrease of the parasitemia across the
infection compared to the control group (Figure 2B). As the
box of Figure 2B shows, the area under the curve (AUC)
highlights the significant differences between the control group
(AUC: 158.60) and treated ones, SChg (AUC: 69.63), SCz (AUC:
87.28), or Chg+SCz (AUC: 54.75) (p < 0.005). The reduction
in parasitemia was reflected in body weight assessment during
this phase, showing substantial differences in all treated mice in
comparison to controls (Figure 2C). Thus, control mice weight
loss correlated with high parasitemia and 100% of mortality at
34 dpi (Figure 2D). In contrast, mice receiving the therapeutic
vaccine based on Salmonellas carrying both Cz and Chg DNAs
had a survival rate of 75% (∗p < 0.05), while in mice treated with
SCz or SChg, the survival rates were 60% and 40%, respectively
(Figure 2D).
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FIGURE 1 | Cloning and characterization of Chg. (A) Digestion of pET23a+-Chg construction with the NdeI and HindIII restriction enzymes released the 400-bp Chg
insert. (B) SDS-PAGE analysis of rChg expression in E. coli BL21 and purification under native condition. Lane 1: MW marker; Lane 2: IMAC Ni-NTA purified rChg (12
kDa) stained with Coomassie Brilliant Blue. (C) Relative enzymatic activity of T. cruzi epimastigote lysate (5µM) in the presence of rChg (10µM) or synthetic inhibitor
E-64 (10µM) on the fluorogenic substrate Z-Gly-Pro-AMC (6 µg) measured as relative fluorescent units (RFUs) and expressed as the log of the percentage of the
fluorescence units as a function of time. (D) Cysteine protease activity of the rNtCz in the absence or presence of increasing concentrations of rChg (0.01–10 µg).
FIGURE 2 | Protection against T. cruzi challenge. (A) Acute model of infection: C3H/HeN mice infected with T. cruzi were treated during the acute phase of infection at
0, 10, and 20 dpi, with three doses of Salmonella transporting Cz and/or Chg together with GM-CSF (SCz, SChg, and SChg+SCz, respectively). (B) Parasitemia
curve after a lethal challenge (insert) AUC of parasitemia. (C) Change in body weight of immune-treated mice. (D) Survival rate curve evaluated every 2–3 days. These
results are representative of at least three independent experiments. One-way ANOVA plus Dunnett’s posttest or Tukey’s posttest and log-rank test for survival curves
were used. Results are expressed as mean ± standard error (n = 5 per group), *p < 0.05, ***p < 0.001.
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SChg+SCz Therapeutic Vaccine After a
Sublethal Infection Enhances
T. cruzi-Specific Immune Response
To study the effect of the immunotherapies on the specific
immune response, at the end of the acute phase (35 dpi) or the
chronic phase (120 dpi) of the parasite infection, another set of
mice was infected with a sublethal dose (50 RA trypomastigotes
per mouse) and treated as previously describe (Figure 2A). The
presence of specific IgG antibodies against immobilized rCz,
rChg, and a T. cruzi lysate F105 was monitored when the acute
phase of infection was overcome, at 35 dpi (Figure 3). At that
time, a significant increase in IgG antibodies against rCz and
F105 was observed in mice treated with SCz and SChg+SCz
(Figures 3B,C), but not in the SChg-treated mice. By contrast,
this group had significant rChg-specific IgG titers compared
to controls (Figure 3A). Notably, infected and vaccinated mice
developed a strong humoral immune response to the immunizing
antigen in spite of the ongoing T. cruzi infection. When the
immune response was analyzed against the natural antigens
present in the parasites (F105), a significant antibody titer was
observed only in groups that received Cz in the formulation.
Just the group that received both antigens (SChg+SCz) had
a significant antibody response against all parasite antigens
(Figures 3A–C). The lack of reactivity against F105 in sera from
the SChg group could be related with the fact that Chg is much
less represented in F105 than Cz, which is a major antigen.
Furthermore, the specific cellular immune response was
analyzed in vivo by a delayed hypersensitivity test (DTH). As
expected, at the end of the acute phase, the groups treated
with the different strategies responded in a significant way to
the stimulation with their corresponding antigen, rCz or rChg
(Figures 3D,E).
The Immune Response Elicited by the
SChg+SCz Therapeutic Vaccine Is Long
Lasting and Persists During the Chronic
T. cruzi Infection
To further characterize the performance of the therapeutic T.
cruzi vaccines, the elicited immune response was also analyzed
during the chronic phase of the infection (120 dpi). We observed
that the humoral immune responses against rChg and rCz were
slightly increased compared to those observed at the end of the
acute phase (35 dpi) for all groups analyzed. This is mainly for
SChg+SCz-treated mice which showed significant differences to
the control group (Figures 4A–C).
The DTH at this time point showed a significant increase
(∗p < 0.01) of the in vivo specific cellular immune response
against the antigens that were administered during the therapy
(Figures 4D,E), according to what was observed at the end of the
acute stage of the infection.
In addition, 100 days after last immunization, we evaluated
ex vivo the lymphoproliferative response of splenocytes from
vaccinated mice upon the restimulation with each antigen: rChg,
rCz, or F105. Spleen cells from SCz alone or in combination
with SChg significantly proliferate in response to rCz and F105
(Figures 4F–H).
IFN-γ is an inflammatory cytokine crucial for immunity
against T. cruzi, involved in the control of systematic
parasite dissemination (38, 39). At 120 dpi, we observed a
significant increase in the percentage of IFN-γ-producing cells in
splenocytes from SChg+SCz-treated mice after being stimulated
with Cz, Chg, or F105, compared to untreated mice infected with
T. cruzi. SCz spleen cells responded to Cz or F105 incubation,
while SChg only responded to the parasite’s lysates (Figure 4I).
SChg+SCz Therapeutic Vaccine Prevents
Tissue Damage of the Chronic Infection
Then, we analyzed if the therapeutic vaccines administered
during the acute phase of the parasite infection were able to
prevent the tissue damage associated to the chronic phase of
T. cruzi infection. To this purpose, at day 100 after the last
vaccine doses (120 dpi), three parameters were evaluated: serum
levels of CK and CK-MB enzymes, histological analysis of tissue
inflammation, and parasitism in skeletal and cardiac tissues.
Serum levels of CK and CK-MB enzymes were assessed as
an indicator of muscle injury. As can be seen in Figure 5A, the
CK and CK-MB values were lower in all mice that received the
therapeutic vaccines compared to nontreated controls. However,
these differences were only significant compared to SControl
(CK: 52.4± 13.9 IU/L; CK-MB: 26.4± 6.6 IU/L) in the group that
received the Salmonella with the combination of both antigen
DNAs SChg+SCz (CK: 4.7 ± 1.0 IU/L; CK-MB: 6.6 ± 1.1 IU/L),
reflecting a significant reduction in muscle damage.
In addition, histological studies of T. cruzi target tissues
were performed. We observed low levels of pericardial infiltrates
mainly in the right ventricular area without significant
differences between treated and nontreated control groups
when cardiac tissues were analyzed (results not shown).
However, histological sections of skeletal muscle showed
necrosis of muscle fibers and numerous multifocal and diffuse
inflammatory infiltrates in the control group (Figure 5B). By
contrast, all treated groups presented few necrotic zones and
isolated nonspecific inflammatory foci (Figures 5C–E). The
tissue inflammation was analyzed through a semiquantitative
comparative analysis of the different groups, showing that this
protective effect was observed mainly in those that received
SCz as a monocomponent or bicomponent therapeutic vaccine
(Figure 5F).
To determine T. cruzi persistence, the parasite load in target
tissues was determined by quantitative PCR (qPCR). T. cruzi
equivalents in cardiac tissues were very low and presented no
significant differences in vaccinated animals compared to control
mice. However, when parasite loads were analyzed in skeletal
muscles, a significant difference was detected between groups
(Figure 5G). The control group presented parasite loads between
6 and 10 times higher than those in animals that received the
mono-therapeutic vaccine. A striking difference with SControl
was observed in animals treated with the combined formulation
(SChg+SCz). Importantly, this reduction of parasitic load was
more than 100 times. Notably, a significant difference was
observed between the groups immunized only with one antigen
and the combined treatment (Figure 5G), highlighting the higher
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FIGURE 3 | Immune response in mice treated during the acute phase of T. cruzi infection. Mice infected with a sublethal dose of T. cruzi were treated at 0, 10, and 20
dpi with doses of Salmonella carrying the DNA of Chg and/or Cz together with the GM-CSF. Antibody immune response: Total IgG titers of (A) anti-rChg, (B) anti-rCz,
and (C) anti-F105 were measured in sera of all groups obtained at 35 dpi. In vivo cellular immune response: Footpad thickness was measured before and 48 h after
intradermal inoculation of (D) rChg or (E) rCz. The bars represent the average (n = 5 per group) of three representative experiments. *p < 0.05, **p < 0.01,
***p < 0.001.
efficacy of the SChg+SCz vaccine compared with the mono-
therapeutic vaccines.
Tissue Damage Prevention Is Achieved by
SChg+SCz Therapeutic Vaccine Even
Administered in the Chronic Phase of
T. cruzi Infection
After the promising results observed upon the administration
of the therapeutic vaccines during the acute phase, conducted
using the acute model described in Figure 2A, we evaluated
the performance of the vaccines when administered during the
chronic phase of the infection (Figure 6A). T. cruzi-infectedmice
were treated with three doses of the corresponding vaccines on
100, 110, and 120 dpi. At 220 dpi, mice were euthanized, and
different parameters were analyzed to assess tissue damage and
parasite persistence.
Serum levels of the enzymes CK and CK-MB were
significantly lower in SChg+SCz animals (CK: 8.9 ± 3.3 IU/L
and CK-MB: 7.0 ± 1.8 IU/L) with respect to control animals
(CK: 60.7 ± 17.4 IU/L and CK-MB: 51.2 ± 14.6 IU/L)
(Figure 6B). In accordance with these results, the histological
analysis of skeletal muscle showed confluent foci of mononuclear
inflammatory infiltrate with necrosis of the muscle fibers in
SControl group (Figure 6C). By contrast, in mice treated with
the therapeutic vaccines, the foci of mononuclear inflammatory
cells were isolated with poor or no necrosis of the skeletal
fibers (Figures 6D–F). Moreover, animals that received the
SChg+SCz vaccine showed isolated inflammatory mononuclear
cells with interstitial and perivascular localization. These results
are summarized in Figure 6G.
To analyze parasite persistence in target tissues, T. cruzi
equivalents were determined by qPCR. Again, parasite load in
cardiac tissues was very low and did not show differences between
groups. However, T. cruzi equivalents detected in the skeletal
muscle of infected mice treated late during the chronic phase
of the infection were significantly lower compared to those in
SControl (Figure 6H).
By contrast, serum enzymatic activity of CK and CK-MB and
histopathological analysis of tissue and T. cruzi equivalents by
qPCR in skeletal and cardiac tissues of 220-day-old noninfected
mice are shown in Supplementary Figure 1. As expected,
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FIGURE 4 | Immune response elicited by the therapeutic vaccine at 120 dpi, in mice treated during the acute phase of T. cruzi infection. Mice infected with a sublethal
dose of T. cruzi were treated with three doses of Salmonella at 0, 10, and 20 dpi (n = 5 per group), and the immune response generated was analyzed at 120 dpi. The
IgG titers (A) anti-rChg, (B) anti-rCz, and (C) anti-F105 were measured in sera at 120 dpi. Cellular response: The in vivo DTH assay was performed by measuring the
plantar footpad before and 48 h after intradermal inoculation of (D) rChg or (E) rCz; results are expressed as the differences in thickness. Splenocytes from mice
sacrificed at 120 dpi were restimulated with 10µg/ml (F) rCz, (G) rChg, or (H) F105 for 5 days, and thymidine uptake was determined. The results are expressed as
the differences between the cpm of stimulated and baseline cells. (I) Intracellular production of INF-γ, determined by flow cytometry, after the stimulation of the
splenocytes with the different antigens. These results are representative of at least three independent experiments. *p < 0.05, **p < 0.01.
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FIGURE 5 | Prevention of tissue damage by vaccine treatment during the acute phase of the parasite infection. (A) Enzymatic activity of CK and CK-MB enzymes
represented as international units (IU/L). (B–E) Representative image of hematoxylin–eosin-stained skeletal muscle samples taken at day 100 after the last
immunization; magnification: 40× and the inbox 100×. Animals showed (B) multiple confluent foci and necrosis with diffuse distribution (SControl); (C) nonconfluent
mononuclear inflammatory infiltrate (SChg); (D) isolated foci of mononuclear inflammatory infiltrate (SCz); (E) few and isolated infiltrates (SChg+SCz). (F)
Semi-quantified inflammation expressed as inflammation index: (1) isolated foci; (2) multiple nonconfluent foci; (3) inflammatory confluent foci; and (4) multiple diffuse
foci (40). (G) Parasitism in skeletal and cardiac tissues by qPCR at day 100 after the last immunization. Parasite burden in each tissue was expressed as T. cruzi
equivalents per 50 ng of total DNA referred to a calibration curve previously constructed containing known concentrations of T. cruzi epimastigotes. These results are
representative of at least three independent experiments, each one being carried out with five animals per group. *p < 0.05, **p < 0.01, ***p < 0.001; ###p < 0.01.
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FIGURE 6 | Prevention of T. cruzi-associated tissue damage by the vaccines administered at the chronic phase of the parasite infection. (A) Scheme of the chronic
model of infection: C3H/HeN mice infected with T. cruzi received three doses of the SControl, SChg, SCz, or SChg+SCz on 100, 110, and 120 dpi (n = 5 per group).
(B) Enzymatic activity of CK and CK-MB enzymes represented as international units (IU/L). (C,D) Histopathological analysis of skeletal tissue samples at 220 dpi
showed (C) confluent foci of mononuclear inflammatory infiltrate with necrosis of the muscle fibers in SControl; (D) isolated foci of mononuclear inflammatory cells with
(Continued)
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FIGURE 6 | interstitial and perivascular predominance (SChg); (E) nonconfluent mononuclear cells surrounding muscle fibers and interstitial edema (SCz); and (F)
isolated mononuclear cells at the interstitial and perivascular level (SChg+SCz). (G) Inflammation semi-quantified and expressed as an index of inflammation: (1)
isolated foci; (2) multiple nonconfluent foci; (3) inflammatory confluent foci; and (4) multiple diffuse foci (40). (H) Parasite load in skeletal and cardiac tissues determined
by qPCR at 220 dpi. Parasite burden in each tissue was expressed as T. cruzi equivalents per 50 ng of total DNA. Results were referred to a calibration curve
previously constructed containing known concentrations of T. cruzi epimastigotes. These results are representative of at least three independent experiments.
*p < 0.05, **p < 0.01, ***p < 0.001; ###p < 0.01.
noninfected mice were negative by qPCR. CK and CK-MB
values in these mice were similar to those in infected and
SChg+SCz-vaccinated mice. In noninfected mice, we observed
a conserved architecture of both skeletal and cardiac tissues
(Supplementary Figure 1), indicating that our treatments were
not able to completely avoid skeletal tissue damage. However,
the combination of SChg+SCz strongly protected the tissue from
damage compared with nontreated mice.
Considering the lack of effective therapeutics during the
chronic phase of T. cruzi infection, these results suggest
that the SChg+SCz-based vaccine would be a promising
immunotherapeutic strategy with the potential to decrease the
prevalence of Chagas disease.
DISCUSSION
Therapeutic vaccines for indeterminate and chronic Chagas
disease not only would provide health benefits but also result
in economic benefits (15). Hence, millions of people are waiting
for a development of anti-T. cruzi vaccines for prophylactic
and therapeutic purposes to stop Chagas disease progression.
Even though etiologic treatment based on nifurtimox and
benznidazole is undisputed in the acute phase, achieving cure
rates between 65 and 80%; trypanocidal treatment in the chronic
stages of the disease remains controversial because of significant
toxicity and the unproven role in preventing progression to
cardiomyopathy (11, 12, 41, 42). What worsens the situation is
that just a reduced percentage of infections are detected in the
acute phase due to mild symptoms.
In the last few years, a better understanding of the protective
immune responses that can effectively arrest T. cruzi survival
in mammalian host provides the fundamentals for a rational
design of a prophylactic and therapeutic vaccine against Chagas
disease (22). Anti-T. cruzi strategies had been focused on
targeting specific metabolic biochemical pathways or parasite-
specific enzymes, as well as noninvasive immunization routes
(23, 24). Most of these strategies need potent adjuvant to
obtain the desirable response to improve vaccine efficacy (43).
Recently, DNA vaccines have become an effective tool in a
wide variety of preclinical models and have been adopted by
several researchers. The intramuscular injection of the plasmid
DNA encoding several surface antigens or secreted by T. cruzi
has been studied as DNA vaccine (5, 44, 45). However, it is
known that after intramuscular DNA injection, the amount of
DNA available for gene expression is very low, which means
that high initial amounts of the plasmid must be applied to
obtain satisfactory results (25, 46). The difficulties with naked
DNA prompted research into DNA delivery systems using
attenuated viruses, bacteria and parasites, liposomes, virosomes,
microspheres, nanoparticles, and physical delivery systems, such
as electroporation, microinjection, gene gun, tattooing, laser, and
ultrasound (38, 47–49).
In our laboratory, we took advantage of attenuated Salmonella
enterica serovar Typhimurium aroA that can be administered
orally and is easily produced, facilitating its implementation in
vaccination campaigns. We have previously demonstrated the
efficacy of this transport system as prophylactic vaccines to T.
cruzi infection (19, 21, 24, 50, 51). Based on these promising
results, we have evaluated the therapeutic effect of Salmonella
as a DNA delivery system of Cz upon the coadministration with
GM-CSF as adjuvant with good performance (25). With the aim
to further increase the therapeutic effect of the vaccine, in the
present work, we included Chg, a natural inhibitor of cysteine
proteases, as a new immunogen against T. cruzi infection.
A multicomponent therapy might induce a robust parasite-
specific immune response even in late infection, controlling
tissue damage and preventing Chagas disease progression.
We first cloned Chg DNA in a prokaryotic expression
plasmid and expressed the recombinant protein. The activity
analysis demonstrated that rChg is properly folded, interacts
with rCz, and is active as a protease inhibitor. Then, we
cloned Chg in a eukaryotic expression plasmid and evaluated
whether its combination with the plasmid encoding Cz was
able to control an ongoing acute and chronic T. cruzi
infection in mice when transported by Salmonella as a DNA
delivery system. Interestingly, we found that the bicomponent
immunotherapeutic vaccine based on Salmonella (SChg+SCz)
was able to improve the performance obtained by each antigen
as a mono-therapeutic vaccine. The efficacy would be due,
at least in part, to the high humoral and cellular responses
elicited in SChg+SCz not only to the antigens included in
the vaccine (Chg and Cz) but also against the whole parasite
as observed when immobilizing the F105 lysate in ELISAs or
by the IFN-γ production by spleen cells upon restimulation
with the same parasite homogenate. In addition, SChg+SCz-
treated mice displayed a significant cellular immune response
against both antigens compared to untreated mice or mice
that receive a mono-therapeutic vaccine, which could decrease
parasite replication inside the host.
Our results are in line with diverse approaches exhibiting
the efficacy of several T. cruzi antigens (ASP-2, enolase, TSA-
1, and Tc24) to control T. cruzi infection when they are
tested as a therapeutic vaccine during the acute phase of the
parasite infection (47, 48, 52–54). Nevertheless, only a few
groups evaluated the performance of a therapeutic vaccine
when it is administered during the chronic phase of T. cruzi
infection (38, 43, 55–57). In that regard, the effectiveness of
the multicomponent therapeutic vaccine SChg+SCz, when it is
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orally administered during the chronic phase of the infection,
becomes evenmore relevant. Likewise, like the response observed
by a treatment delivered by type 5 recombinant adenoviruses
where the IFN-γ-mediated immunity was enhanced (38),
treatment of chronically infected mice with DNA of Cz
and Chg delivered by Salmonella displayed a robust cellular
immune response with high levels of IFN-γ secretion upon the
restimulation with T. cruzi antigens. This is true, particularly,
in treatments that include the Cz antigen. Treating mice during
the acute phase with the multicomponent vaccine (SChg+SCz)
would allow a rapid T-cell response in case of T. cruzi reactivation
or reinfection and, therefore, a major control of the parasite
dissemination to the host tissues. This supports the idea of
other authors that IFN-γ is important in mediating an effective
immunity against T. cruzi (39).
We analyzed the ability of the immunotherapy to prevent
or decrease the onset of tissue damage during the chronic
stage of parasite infection. Serum activity of the CK enzyme
and the cardiac isoform CK-MB, analyzed as highly specific
markers of myocardial injury, showed that SChg+SCz-treated
mice, independently of the time of administration, presented a
mean level 10 times lower than that observed in infected and
untreated mice. Importantly, the SChg+SCz immunotherapeutic
vaccine administered at the chronic phase of T. cruzi infection
was able to improve several parameters that were already
altered at the start of the treatment. For example, the serum
level of CK-MB in infected and nontreated mice at 100 dpi
was 26.4 ± 6.6 IU/L (Figure 5B). When immunotherapy was
administered at the chronic phase, CK-MB levels were reduced
to 7.0 ± 1.8 IU/L at 220 dpi, values similar to those in normal
tissues (Supplementary Figure 1A); otherwise, in the absence of
treatment, it reached levels of 51.2 ± 14.6 IU/L (Figure 6B).
This decrease in tissue damage by chronic immunotherapy, also
described by Pereira et al. (38), is really encouraging since current
treatment with nifurtimox or benznidazole at the chronic phase
of the parasite infection in humans reduces parasite load but
does not improve the clinical outcome of Chagas disease (11).
As murine and human infections differ in several aspects of the
parasite–host relationship, including duration of infection, these
results support the evaluation of anti-T. cruzi immunotherapy in
human clinical trial basis.
Effectively, these results are a clear evidence that SChg+SCz
as an oral therapeutic vaccine administered during the acute or
chronic stage of infection has potential to delay the progression
of Chagas disease and could be an effective tool to mitigate the
damage associated to Chagas disease. In addition, despite the
fact that tissues of infected-treated mice are not preserved to
the same architecture of the organs of noninfected nontreated
age-matched mice (Supplementary Figures 1C,D), there were
only a few and isolated inflammatory foci. These tissue damage
parameters have a clear correspondence with the parasitic load
analyzed by qPCR in cardiac and mainly skeletal muscles,
since mice immunized with the bicomponent vaccine presented
the highest reduction compared with infected control and
experimental groups. These results reinforce the hypothesis
that the reduction in tissue parasitism highly correlates
with damage in target tissues. Regarding the performance
of SChg+SCz, we demonstrated its immunogenicity, being
able to prime a more robust immune response. Moreover,
with this multivaccination strategy, we were able to improve
the efficacy conferred with the administration of the DNA
antigens individually. It is also encouraging since the hopeful
SChg+SCz treatment could be administered when an acute
T. cruzi infection is suspected or confirmed. Interestingly,
considering that the diagnosis of a T. cruzi infection is usually
achieved during the chronic phase of the parasite infection,
it is of great importance that a tissue protective effect is
displayed by the multicomponent therapeutic vaccine when
administered on the chronic stage of infection. The major
advantage of this strategy is that it relies on the induction
of multiple effector mechanisms against the pathogen that
may have higher efficacy than conventional treatments to face
the asymptomatic and chronic phase of T. cruzi infection.
Considering animal model limitations and that this pathology
is a dynamic process accounting for organ-specific damage, it
would be interesting to analyze the efficacy of the treatment
using other mouse models and parasite strains that affect
different tissues, such as that made by Francisco et al. (58), in
further communications.
A therapeutic vaccine for Chagas disease may improve or
even replace the treatment with current drugs which have
several side effects and require long-term use that frequently
leads to therapeutic withdrawal. The oral therapeutic vaccine
SChg+SCz would also be an interesting weapon in combined
therapies with parasiticidal drugs, as have been successfully
reported in different pathologies (59, 60) and reviewed by
Bivona (22). With the active replication of the parasite during
the acute T. cruzi infection being kept in mind, it would
be interesting to evaluate if combined therapy administered
during the acute phase of the infection could have a synergism
with the host immune response and the drug activity to
achieve parasite clearance. This immunotherapeutic vaccine
not only would allow targeting different humoral and cellular
elements as well metabolic pathways but also would be able
to reduce doses and drug exposure periods, thus contributing
to the decrease in toxic effects and minimization of the
emergence of drug resistance. Not to be underestimated, as
has been recently reviewed by Rios et al. (61) and proposed
by Dumonteil et al. (62), therapeutic vaccines could be
an excellent tool to avoid future congenital transmission,
which is estimated at 5% in Latin America, preventing the
risk of pregnancy complications like preterm rupture of
membranes and preterm delivery. Although available drugs
are not approved for use during pregnancy, several studies
suggest that reducing maternal parasitemia before conception
reduces the risk of congenital transmission (63–65), and it was
recently estimated that a therapeutic vaccination of Chagas-
positive pregnant women would be cost-effective and cost
saving (66).
With the bicomponent therapeutic vaccine SChg+SCz, we
were able to improve the efficacy conferred by the administration
of the DNA antigens individually. This treatment increased the
survival of mice upon a lethal T. cruzi challenge and successfully
decreased tissue damage associated to T. cruzi infection. These
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results indicate that SChg+SCz could be a promising strategy in
the search of an anti-Chagas therapy to be administered in either
the acute or chronic phase of the infection.
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